Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Aarhus University · Aarhus University Hospital · +29 more institutions
Abstract
The only current strategy to test efficacy of novel interventions for sustained HIV control without antiretroviral therapy (ART) among people with HIV (PWH) is through an analytical treatment interruption (ATI). Inclusion of ‘placebo’ controls in ATIs poses ethical, logistical, and economic challenges. To understand viral dynamics and rates of post-treatment control (PTC) after ATI among PWH receiving either placebo or no intervention, we undertook an individual-participant data meta-analysis. In total, 24 eligible prospective studies with 382 individuals with ≥5 plasma HIV RNA viral loads (pVLs) within the first 84 days post-ATI were included. Early-ART was defined as ART initiation within 6 months of HIV…
Citation impact
- FWCI
- 51.02
- Percentile
- 100%
- References
- 50
Authors
30- JDJesper Damsgaard GunstCorresponding
Aarhus University, Aarhus University Hospital
- JGJesal Gohil
NIHR Imperial Biomedical Research Centre, Imperial College London
- JZJonathan Z. Li
Brigham and Women's Hospital, Harvard University
- RJRonald J. Bosch
Harvard University
- CWCaitlin White
National Institutes of Health Clinical Center
Topics & keywords
- Interquartile range
- Medicine
- Viral load
- Antiretroviral therapy
- Psychological intervention
- Placebo
- Human immunodeficiency virus (HIV)
- Prospective cohort study
- Good health and well-being
Funding
- BABill and Melinda Gates FoundationAwards: AI169768, OPP1204692
- ATamfAR, The Foundation for AIDS Research
- AGACT Government
- CDCentres de Recerca de CatalunyaAwards: SGR 615, SGR 653
- NINational Institute for Health and Care Research
- ICImperial College London
- ICImperial College Healthcare NHS Trust
- ECEuropean CommissionAwards: 101057548, 681137-EAVI2020, 681137, 602570, HEALTH-2013
- GDGeneralitat de Catalunya
- LLundbeckfondenAwards: R381–2021–1405, R313-2019-790, R381-2021-1405
- DFDanmarks Frie ForskningsfondAward: 9060-00023B
- HLH. Lundbeck A/S
- NINational Institutes of HealthAwards: UM1 AI106701, AI068634, P01-AI131568, AI164570, UM1 AI068636, AI131568, AI068636, AI106701, AI164561, AI169768, AI060354
- HEHORIZON EUROPE Framework Programme
- IDInstituto de Salud Carlos IIIAwards: SAF-2017-88089-R, RD16/0025
- NINational Institute of Allergy and Infectious DiseasesAwards: AI068634, 1 UM1 AI164561-01, AI106701, P01-AI131568, AI060354, UM1 AI106701, UM1 AI164561, AI164570, AI068636, UM1 AI164570, UM1 AI068636, AI150396
- FHFP7 HealthAward: 602570
- NDNHLBI Division of Intramural Research